Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.31 |
| ▸ | PLA2G4A | P47712 | 2/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18968971 | 0.99 | MMP12 (0.31) | MMP12MMP13PLA2G2APLA2G4A | |
| SCHEMBL18969107 | 0.96 | AHR (0.30) | AHRMEN1KMT2AMAPTTHRB | |
| SCHEMBL18968991 | 0.96 | AHR (0.32) | MMP12MMP13AHRMEN1KMT2A | |
| SCHEMBL18968989 | 0.93 | CHRNA1 (0.35) | — | |
| SCHEMBL18968974 | 0.93 | — | — | |
| SCHEMBL18968977 | 0.91 | AHR (0.33) | AHRMEN1KMT2AMAPT | |
| SCHEMBL18968986 | 0.89 | MMP12 (0.34) | MMP12MMP13PLA2G2APLA2G4AAHR | |
| SCHEMBL17827475 | 0.88 | MMP12 (0.33) | MMP12MMP13PLA2G2APLA2G4AAHR | |
| SCHEMBL18969088 | 0.88 | MMP12 (0.33) | MMP12MMP13PLA2G2APLA2G4AAHR | |
| SCHEMBL17827454 | 0.88 | MMP12 (0.33) | MMP12MMP13PLA2G2APLA2G4AAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10361374-B2 | Amine compound and organic light emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2019-07-23 | — | — | US | disclosed |
| US-20170170402-A1 | AMINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170170402-A1 | AMINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170170402-A1 | AMINE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME | AOC2, MAOA, AOC3 | MMP12 3839/4885MMP13 4427/4885PLA2G2A 3806/4885 |
| US-10361374-B2 | Amine compound and organic light emitting device including the same | AOC2, MAOA, AOC3 | MMP12 3839/4885MMP13 4427/4885PLA2G2A 3806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.